PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Obamacare
Into the Extrapolation Machine: How We Joined the Elite 58%
By Les Funtleyder.
The problem we see with the polarity of views is that both sides seem to be cranking up the extrapolation machine and use single studies/data points to draw broad conclusions to gin up opinions about ACA’s success or lack thereof. With respect to investing, uncertainly caused by media/pundit noise often depresses valuations in [...]
Posted in Guest Blog, Op-Ed, healthcare Also tagged ACA, extrapolation, Health Reform, healthcare, healthcare costs, Investment, Kaiser Family Foundation, NEJM, Oregon experiment, utilization Leave a comment
Congress 'Tip Toes' Around Obamacare
by Tom Norton
Of the many issues involved with the actual implementation of the 2010 Affordable Care Act, aka, “Obamacare”, few are more intriguing to me than those that personally impact Members of Congress (MOCs). Here’s a good example of what I’m talking about — Today, on Capitol Hill, MOCs, along with thousands of their personal [...]
Posted in Guest Blog, Legal, Strategy, healthcare Also tagged Affordable Care Act, Congress, healthcare, HHS, Politics, POTUS, Sen. Charles Grassley (R-IA), state health exchanges 3 Comments
Budget Cutters Propose Big Hits on Pharma
By Jill Wechsler, Washington Correspondent.
The Obama administration’s budget plan for fiscal year 2014 apparently assumes that the pharmaceutical industry can support Medicare and other health programs through changes in drug coverage and payments. It also relies on industry fees to keep the Food and Drug Administration up and running. Meanwhile, FDA and other public health [...]
Posted in Guest Blog, Op-Ed, healthcare Also tagged buget, Cuts, FDA, healthcare reform, NIH, pay-for-delay, sequestration Leave a comment
"Sunshine" Just the Tip of the Iceberg: Pharma and Full Disclosure
“Sunshine” Just the Tip of the Iceberg: Full Disclosure for Pharma:??There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices, writes Jill Wechsler.
Although recent legislation and regulations have greatly expanded the range of information that pharmaceutical companies have to unveil to the public, there’s an escalating [...]
Posted in Guest Blog, Op-Ed, Regulatory, Safety, Strategy, healthcare, pricing Also tagged drug safety, regulatory affairs, Sunshine Act, transparency 1 Comment
Your 2014 Medicaid Sales & Marketing Plans